| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| Treco Douglas A | CEO & Chairman, Director | C/O INOZYME PHARMA, INC., 321 SUMMER STREET SUITE 400, BOSTON | /s/ Sanjay Subramanian, as attorney-in-fact for Douglas A Treco | 2025-07-03 | 0001688192 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | INZY | Common Stock | Disposition pursuant to a tender of shares in a change of control transaction | -$175K | -43.9K | -100% | $4.00 | 0 | Jul 1, 2025 | Direct | F1, F2 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | INZY | Restricted Stock Units | Disposed to Issuer | -150K | -100% | 0 | Jul 1, 2025 | Common Stock | 150K | Direct | F1, F3 | |||
| transaction | INZY | Stock Option (Right to Buy) | Disposed to Issuer | -87K | -100% | 0 | Jul 1, 2025 | Common Stock | 87K | $2.77 | Direct | F1, F4 | ||
| transaction | INZY | Stock Option (Right to Buy) | Disposed to Issuer | -400K | -100% | 0 | Jul 1, 2025 | Common Stock | 400K | $1.06 | Direct | F1, F4 |
Douglas A. Treco is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.
| Id | Content |
|---|---|
| F1 | This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 16, 2025, by and among the Issuer, BioMarin Pharmaceutical Inc., a Delaware corporation ("Parent"), and Incline Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.0001 per share (the "Company Common Stock"), for a price per share of $4.00 (the "Merger Consideration"), without interest and subject to any withholding of taxes required by applicable law. Effective as of July 1, 2025, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and as a wholly-owned subsidiary of Parent (the "Merger"). |
| F2 | Pursuant to the terms of the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each share of Company Common Stock held by the Reporting Person was tendered in exchange for the Merger Consideration, without interest and subject to any withholding of taxes required by applicable law. |
| F3 | Pursuant to the terms of the Merger Agreement, each share of Company Common Stock subject to issuance pursuant to outstanding restricted stock units (each, a "Company RSU Award"), whether vested or unvested that was outstanding immediately prior to the Effective Time, was automatically accelerated, became fully vested, and was cancelled and automatically converted into the right to receive, for each share of Company Common Stock underlying such Company RSU Award, an amount (without interest and subject to deduction for any required withholding under applicable law relating to tax) in cash equal to the Merger Consideration. |
| F4 | Pursuant to the terms of the Merger Agreement, each outstanding option to purchase shares of Company Common Stock ("Company Option"), whether vested or unvested, that was outstanding immediately prior to the Effective Time and had a per share exercise price that was less than the Merger Consideration was automatically accelerated and became fully vested, was cancelled and automatically converted into the right to receive for each share of Company Common Stock underlying such Company Option, an amount (without interest and subject to deduction for any required withholding under applicable law) in cash equal to the excess of the Merger Consideration over the per share exercise price of such Company Option. |